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Key messages
What is the key question?
 ► We aimed to assess the uptake of minimally invasive 
surgery (MIS) and stereotactic body radiation ther-
apy (SBRT) among early stage non- small cell lung 
cancer (NSCLC) cases in the USA, as well as the rate 
of conversions from MIS to open surgery.
What is the bottom line?
 ► Between 2010 and 2014, the uptake of MIS and 
SBRT among patients diagnosed with early stage 
NSCLC increased significantly, while the rate of con-
versions to open surgery decreased significantly.
Why read on?
 ► Continuing the increasing uptake of MIS and SBRT 
may contribute to improving patient care, in particu-
lar with the expected increase in early stage diagno-
ses due to international recommendations and plans 
for the implementation of lung cancer screening.
AbstrAct
background We aimed to assess the uptake of 
minimally invasive surgery (MIS) and stereotactic body 
radiation therapy (SBRT) among early stage (stage 
IA–IIB) non- small cell lung cancer (NSCLC) cases in 
the USA, and the rate of conversions from MIS to open 
surgery.
Materials and methods Data were obtained from the 
US National Cancer Database, a nationwide facility- based 
cancer registry capturing up to 70% of incident cancer 
cases in the USA. We included cases diagnosed with early 
stage (clinical stages IA–IIB) NSCLC between 2010 and 
2014. In an ecological analysis, we assessed changes in 
treatment by year of diagnosis. Among surgically treated 
cases, we assessed the uptake of MIS and whether 
conversion to open surgery took place. For cases that 
received thoracic radiotherapy, we assessed the uptake of 
SBRT.
results Among 117 370 selected cases, radiotherapy 
use increased 3.4 percentage points between 2010 and 
2014 (p<0.0001). Surgical treatments decreased 3.5 
percentage points (p<0.0001). Rates of non- treatment 
remained stable (range: 10.0%–10.6% (p=0.4066)). 
Among surgically treated stage IA cases, uptake of MIS 
increased from 28.7% (95% CI 27.8% to 29.7%) in 2010 
to 48.6% (95% CI 47.6% to 49.6%) in 2014 (p<0.0001), 
while conversions decreased from 17.0% (95% CI 
15.6% to 18.6%) in 2010 to 9.1% (95% CI 8.3% to 
10.0%) in 2014 (p<0.0001). MIS uptake among stages 
IB–IIB was lower and conversion rates were higher, but 
time trends were similar. Uptake of SBRT among stage 
IA receiving thoracic radiotherapy increased from 53.4% 
(95% CI 51.2% to 55.6%) in 2010 to 73.0% (95% CI 
71.4% to 74.6%) in 2014 (p<0.0001). SBRT uptake 
among stage IB increased from 32.5% (95% CI 29.9% 
to 35.2%) in 2010 to 48.2% (95% CI 45.6% to 50.8%) in 
2014 (p<0.0001).
conclusion Between 2010 and 2014, uptake of MIS and 
SBRT among early stage NSCLC significantly increased, 
while the rate of conversions to open surgery significantly 
decreased. Continuing these trends may contribute to 
improving patient care, in particular with the expected 
increase in early stages due to the implementation of lung 
cancer screening.
IntroductIon
Lung cancer is the leading cause of cancer- 
related deaths worldwide.1 2 The majority 
of lung cancer cases are non- small cell lung 
cancer (NSCLC).3 Currently, most NSCLC 
cases are diagnosed with metastatic disease,4 
in which case curative treatment is usually 
not possible.5 However, the number of cases 
diagnosed with potentially curative early stage 
disease is expected to increase in upcoming 
years6 due to the ongoing (USA) and consid-
ered (EU and UK) implementation of lung 
cancer screening.7–9
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While surgical resection is still standard of care for 
early stage NSCLC, the preferred surgical approach has 
shifted from thoracotomy to minimally invasive surgery 
(MIS). MIS includes video- assisted thoracoscopic surgery 
(VATS) and, more recently, robotic- assisted thoracic 
surgery (RATS).5 MIS is associated with less postoperative 
pain, shorter hospital stay, less pulmonary complications 
and improved quality of life compared with thoracotomy, 
without compromising perioperative mortality or short- 
term survival.10–13 Although a recent analysis suggests 
that the uptake of VATS among patients with lung cancer 
in the US Veterans Affairs is increasing,14 the generalis-
ability of these findings to early stage NSCLC cases in the 
general US population remains unknown. In addition, 
the Veterans Affairs analysis did not include cases treated 
with RATS. Also, the current rate of conversions from 
MIS to open surgery and whether this rate has changed 
with the increased uptake of MIS is unclear.
Some patients with early stage NSCLC are unfit for 
surgery due to comorbidity or may prefer not to undergo 
surgery for non- medical reasons. For those patients, 
stereotactic body radiation therapy (SBRT) is now 
recommended as an alternative standard of care.5 SBRT 
concentrates a high dose of radiotherapy on a small 
target volume using only a few fractions. In patients with 
medically inoperable early stage NSCLC, SBRT provides 
local tumour control rates of up to 90% with moderate 
toxicity.15 16 A previous analysis suggested that the uptake 
of SBRT in the USA could still be lagging.17
The degree of uptake of these therapies is topical 
because the effectiveness of the recent recommenda-
tions and plans for lung cancer screening will depend on 
optimal treatment of early stage lung cancer. Therefore, 
we aimed to assess the uptake of MIS and SBRT among 
early stage NSCLC cases in the USA, as well as the rate of 
conversions from MIS to open surgery. We hypothesised 
that the uptake of MIS and SBRT in the USA increases 
over time. This hypothesis was tested in an ecological 
analysis of secular trends in the facility- based US National 
Cancer Database (NCDB).
Methods
data
We extracted all individual- level records from the NCDB 
of persons diagnosed with early stage (ie, clinical stages 
IA, IB, IIA and IIB) NSCLC between 2010 and 2014. The 
NCDB, established in 1989, is a nationwide, facility- based, 
comprehensive clinical surveillance resource oncology 
data set that currently captures 70% of all newly diagnosed 
malignancies in the USA annually, from more than 1500 
affiliated facilities. To ensure the accuracy of treatment 
data we excluded the following groups: non- malignant 
cases; cases not staged using the American Joint Commis-
sion on Cancer (AJCC) seventh edition system;18 cases 
with a history of multiple primary tumours of which lung 
cancer was not the first; cases diagnosed before the date 
from which the reporting facility guarantees accuracy 
of the data; cases that were diagnosed at the reporting 
facility but received therapy elsewhere; cases with more 
than 4 months (ie, 122 days) between diagnosis and 
onset of treatment; and cases for which it was unknown 
whether any treatment was received. These exclusion 
criteria are in concordance with NCDB guidelines and 
with a previous investigation of NCDB data conducted by 
our group.17
statistical analysis
We assessed the proportion of cases that received surgery, 
radiotherapy and no therapy as first course treatment 
by clinical stage and by year of diagnosis. Among surgi-
cally treated cases, we assessed whether the planned 
approach was MIS (which includes VATS and RATS), 
and whether conversion to open surgery took place. If 
a patient received multiple surgeries, the NCDB records 
the surgical approach of the most invasive and definitive 
surgical treatment. In addition, we assessed the extent 
of resection (sublobar, lobectomy or bilobectomy, pneu-
monectomy, or other; see online supplementary methods 
for coding). Because the extent of disease may affect the 
technical difficulty of performing MIS, time trends in the 
uptake of MIS and the rate of conversions were assessed 
by clinical stage and by extent of resection.
For cases that received radiotherapy, we assessed the 
radiation target (thoracic vs non- thoracic). For cases with 
a thoracic radiation target, we further assessed whether 
SBRT or another radiation modality was used. In accor-
dance with a previous report we defined SBRT as thoracic 
radiotherapy with a total radiation dose of at least 45 
Gray over five fractions or less.17 Because the extent of 
disease may affect the feasibility of SBRT, time trends in 
the uptake of SBRT were assessed by clinical stage.
Trends were formally tested using χ2 trend tests. Exact 
binomial 95% CIs were calculated for proportions. All 
analyses were performed using R software V.3.6.1.19 This 
analysis of NCDB data was deemed exempt by the Institu-
tional Review Board at the University of Michigan.
sensitivity analyses
If the surgical approach was unknown we assumed that 
MIS had not taken place. Similarly, we assumed that SBRT 
was not used if the radiation modality was unknown. In a 
sensitivity analysis, we excluded those cases with missing 
data on either of these variables.
A second sensitivity analysis assessed whether time 
trends in the uptake of MIS and SBRT differed by sex 
and by age.
Patient and public involvement statement
Patients or the public were not involved in the design, 
or conduct, or reporting, or dissemination plans of our 
research.
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Figure 1 Flow chart of case selection. ICD-0-3, 
International Classification of Diseases for Oncology, third 
edition; AJCC, American Joint Committee on Cancer.
Table 1 Treatment patterns among early stage non- small cell lung cancer cases by clinical stage at diagnosis and by year of 
diagnosis
Surgery n (%(95% CI))* Radiotherapy n (%(95% CI)) No therapy n (%(95% CI))
Stage
  IA 44 160 (72.2 (71.9 to 72.6))† 13 690 (22.4 (22.1 to 22.7)) † 4673 (7.6 (7.4 to 7.9)) †
  IB 16 902 (64.9 (64.3 to 65.5)) 7043 (27.0 (26.5 to 27.6)) 3029 (11.6 (11.2 to 12.0))
  IIA 9388 (59.1 (58.3 to 59.8)) 5288 (33.3 (32.5 to 34.0)) 2201 (13.8 (13.3 to 14.4))
  IIB 6907 (48.3 (47.5 to 49.1)) 6376 (44.6 (43.8 to 45.4)) 2223 (15.5 (15.0 to 16.1))
Year
  2010 15 016 (67.9 (67.3 to 68.5)) † 5659 (25.6 (25.0 to 26.2))† 2308 (10.4 (10.0 to 10.8)) ‡
  2011 15 194 (67.3 (66.7 to 67.9)) 6044 (26.8 (26.2 to 27.4)) 2287 (10.1 (9.7 to 10.5))
  2012 15 385 (65.8 (65.1 to 66.4)) 6465 (27.6 (27.1 to 28.2)) 2487 (10.6 (10.2 to 11.0))
  2013 15 827 (64.5 (63.9 to 65.1)) 7062 (28.8 (28.2 to 29.3)) 2562 (10.4 (10.1 to 10.8))
  2014 15 935 (64.4 (63.8 to 65.0)) 7167 (29.0 (28.4 to 29.5)) 2482 (10.0 (9.7 to 10.4))
*Patients could receive multiple treatments. Hence, the percentages receiving surgery, radiotherapy and no therapy do not add up to 100%.
†Statistically significant trend (p<0.0001).
‡Statistically non- significant trend (p=0.4066).
results
Patient characteristics
We identified records for 209 627 cases diagnosed with 
early stage (ie, clinical stages IA, IB, IIA and IIB) NSCLC 
between 2010 and 2014. After exclusions, 117 370 cases 
were selected for analysis (see figure 1). Among the 
selected cases, 55 248 (47.1%) were male. Median age at 
diagnosis was 70 years (IQR: 62–77 years). Clinical stage 
at diagnosis was IA for 61 123 cases (52.1%), IB for 26 049 
cases (22.2%), IIA for 15 898 cases (13.5%) and IIB for 
14 300 cases (12.2%).
General treatment patterns
Table 1 presents general treatment patterns by clinical 
stage at diagnosis and by year of diagnosis. Overall, the 
percentage of early stage NSCLC cases receiving surgery 
decreased with advancing stage at diagnosis, from 72.2% 
(95% CI 71.9% to 72.6%) among stage IA to 48.3% (95% 
CI 47.5% to 49.1%) among stage IIB (−23.9 percentage 
points; p<0.0001). Conversely, the percentage receiving 
radiotherapy increased with advancing stage (from 
22.4% (95% CI 22.1% to 22.7%) among stage IA to 
44.6% (95% CI 43.8% to 45.4%) among stage IIB (+22.2 
percentage points; p<0.0001)). Also, the percentage 
of cases receiving no treatment increased from 7.6% 
(95% CI 7.4% to 7.9%) among stage IA to 15.5% (95% 
CI 15.0% to 16.1%) among stage IIB (+7.9 percentage 
points; p<0.0001).
Between 2010 and 2014, the number of early stage 
NSCLC cases that received surgery decreased by 3.5 
percentage points (p<0.0001), from 67.9% (95% CI 
67.3% to 68.5%) in 2010 to 64.4% (95% CI 63.8% to 
65.0%) in 2014. The number of cases that received radio-
therapy increased by 3.4 percentage points (p<0.0001), 
from 25.6% (95% CI 25.0% to 26.2%) in 2010 to 29.0% 
(95% CI 28.4% to 29.5%) in 2014. The percentage of 
cases that did not receive any treatment varied between 
10.0% (95% CI 9.7% to 10.4%) and 10.6% (95% CI 
10.2% to 11.0%) across years 2010–2014, with no partic-
ular time trend (p=0.4066).
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Figure 2 Uptake of minimally invasive surgery among 
early stage non- small cell lung cancer cases between 2010 
and 2014 by clinical stage at diagnosis. (A) The percentage 
of lung cancer surgeries that were started as minimally 
invasive surgery between 2010 and 2014 by clinical stage 
at diagnosis. (B) The percentage of lung cancer surgeries 
which started as minimally invasive surgery that were 
converted to open surgery between 2010 and 2014, by 
clinical stage at diagnosis.
Figure 3 Uptake of minimally invasive surgery among 
early stage non- small cell lung cancer cases between 2010 
and 2014 by extent of resection. (A) The percentage of lung 
cancer surgeries that were started as minimally invasive 
surgery between 2010 and 2014 by extent of resection. 
(B) The percentage of lung cancer surgeries which started 
as minimally invasive surgery that were converted to open 
surgery between 2010 and 2014, by extent of resection. 
Overall, only 1.3% of surgically treated cases received 
surgery of ‘other’ extent. Therefore, time trends were not 
assessed for this category.
Online supplementary table 1 shows the extent of 
resection among surgically treated cases by clinical stage 
and year of diagnosis. Overall, 18.1% (95% CI 17.8% to 
18.4%) received a sublobar resection, 77.0% (95% CI 
76.7% to 77.3%) received a lobectomy or a bilobectomy, 
and 3.7% (95% CI 3.6% to 3.8%) received a pneumonec-
tomy. Only minor changes in the distribution of surgical 
extent occurred over time. However, the percentage 
receiving sublobar resection decreased from 24.3% (95% 
CI 23.9% to 24.7%) among stage IA to 9.4% (95% CI 
8.8% to 10.2%) among stage IB (−14.9 percentage points; 
p<0.0001). Conversely, the percentage receiving pneu-
monectomy increased with advancing stage, from 0.8% 
(95% CI 0.7% to 0.9%) among stage IA to 13.2% (95% 
CI 12.4% to 14.0%) among stage IIB (+12.4%; p<0.0001).
uptake of MIs and rate of conversions
Figure 2A shows the trend in uptake of MIS by clinical stage 
among those treated surgically between 2010 and 2014. 
Among surgically treated stage IA cases (n=44 160), the 
uptake of MIS increased by 19.9 percentage points, from 
28.7% (95% CI 27.8% to 29.7%) in 2010 to 48.6% (95% 
CI 47.6% to 49.6%) in 2014. Although the percentage 
receiving MIS in 2010 was lower for stages IB–IIB than for 
stage IA (22.9% (95% CI 21.5% to 24.3%) among stage IB, 
20.0% (95% CI 18.2% to 21.8%) among stage IIA, 15.7% 
(95% CI 13.8% to 17.8%) among stage IIB), the increase 
over time was similar (+18.5,+15.1 and +16.8 percentage 
points, respectively). Whereas the uptake of MIS increased 
over time, the rate of conversions to open surgery among 
these cases decreased. For stage IA, the rate of conversions 
decreased by 7.9 percentage points, from 17.0% (95% CI 
15.6% to 18.6%) in 2010 to 9.1% (95% CI 8.3% to 10.0%) 
in 2014 (figure 2B). The rate of conversions was higher 
for stages IB–IIB compared with stage IA in 2010, but the 
decreases over time were similar (range across stages: −7.0 
to −10.6 percentage points). All stage- specific trends in the 
uptake of MIS and the rate of conversions to open surgery 
were statistically significant (p<0.0001).
Time trends in the uptake of MIS and the rate of 
conversions to open surgery by extent of resection are 
shown in figure 3. In 2010, the uptake of MIS was highest 
among those receiving a sublobar resection (33.6% (95% 
CI 31.8% to 35.4%)), followed by lobectomy or bilobec-
tomy (23.6% (95% CI 22.8% to 24.4%)) and pneumo-
nectomy (11.2% (95% CI 8.8% to 14.0%)). Between 
2010 and 2014, uptake of MIS increased for all extents 
of resection (for sublobar resection:+20.8 percentage 
points (p<0.0001); for lobectomyor bilobectomy: +19.0 
percentage points (p<0.0001); for pneumonectomy: 
+8.9percentage- points (p=0.0002)). In 2010, rates of 
conversions were highest for those receiving pneumo-
nectomy (36.8% (95% CI 25.4% to 49.3%)), followed by 
those receiving lobectomy or bilobectomy (20.9% (95% 
CI 19.4% to 22.5%)), and finally those who received a 
sublobar resection (11.8% (95% CI 9.7% to 14.1%)). 
The rate of conversions decreased over time for sublobar 
resections (−5.4 percentage points; p<0.0001) and for 
lobectomy or bilobectomy (−9.4 percentage points; 
p<0.0001), but not for pneumonectomy (p=0.5813).
uptake of sbrt
Among early stage NSCLC cases treated with radiotherapy, 
95.5% (95% CI 95.3% to 95.7%) received thoracic radi-
otherapy. Figure 4 shows the uptake of SBRT among 
these cases by clinical stage. Among the 13 252 stage IA 
NSCLC cases that received thoracic radiotherapy, the use 
of SBRT increased from 53.4% (95% CI 51.2% to 55.6%) 
in 2010 to 73.0% (95% CI 71.4% to 74.6%) in 2014 
(+19.6 percentage points). The uptake of SBRT among 
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Figure 4 Uptake of stereotactic body radiation therapy 
among early stage non- small cell lung cancer cases treated 
with thoracic radiotherapy between 2010 and 2014 by 
clinical stage at diagnosis.
the 6729 stage IB NSCLC cases that received thoracic 
radiotherapy increased by 15.7 percentage points, from 
32.5% (95% CI 29.9% to 35.2%) in 2010 to 48.2% (95% 
CI 45.6% to 50.8%) in 2014. However, during the same 
period the percentage receiving SBRT remained low 
among the 4962 stage IIA cases and the 6005 stage IIB 
cases that received thoracic radiotherapy. The uptake of 
SBRT among stage IIA was 5.5% (95% CI 4.2% to 7.2%) 
in 2010 and 10.5% (95% CI 8.7% to 12.6%) in 2014 (+5.0 
percentage points). Among stage IIB, the uptake of SBRT 
was 4.8% (95% CI 3.7% to 6.2%) in 2010 and 9.6% (95% 
CI 8.0% to 11.4%) in 2014 (+4.8 percentage points). All 
stage- specific time trends in the uptake of SBRT were 
statistically significant (p<0.0001).
sensitivity analyses
Data on the surgical approach or radiation modality 
were missing for 5089 cases. After excluding those cases, 
the uptake of MIS and SBRT were higher, although 
stage- specific time trends remained similar (see online 
supplementary figures 1 and 2). For example, among 
42 773 surgically treated stage IA cases, the uptake of MIS 
increased by 20.6 percentage points, from 29.2% (95% 
CI 28.2% to 30.2%) in 2010 to 49.8% (95% CI 48.8% 
to 50.8%) in 2014 (p<0.0001). The rate of conversions 
to open surgery among stage IA cases decreased from 
17.1% (95% CI 15.6% to 18.6%) in 2010 to 9.1% (95% 
CI 8.3% to 10.0%) in 2014 (−8.0 percentage points; 
p<0.0001). Among 12 241 stage IA cases that received 
thoracic radiotherapy, the uptake of SBRT increased 
from 59.0% (95% CI 56.7% to 61.2%) in 2010 to 77.8% 
(95% CI 76.3% to 79.3%) in 2014 (+18.8 percentage 
points; p<0.0001).
The uptake of MIS and SBRT increased over time for 
both sexes and all age groups (see online supplemen-
tary figures 3–6). In addition, the rate of conversions to 
open surgery decreased over time for both sexes and all 
age groups. The uptake of VATS and SBRT were slightly 
higher among women than among men, whereas the rate 
of conversions was slightly lower. For example, the uptake 
of VATS among men in 2010 was 23.5% (95% CI 22.5% 
to 24.5%), compared with 26.6% among women (95% CI 
25.7% to 27.6%). The uptake of SBRT was notably higher 
for more advanced ages (see online supplementary figure 
6). For example, the uptake of SBRT in 2010 was 5.3% 
(95% CI 2.1% to 10.5%) among those younger than 50 
years, compared with 38.8% (95% CI 36.2% to 41.5%) 
among those older than 80 years.
dIscussIon
General treatment patterns
Patterns of care indicate that most early stage NSCLC 
cases receive surgery and/or radiotherapy. However, 
whereas the percentage receiving radiotherapy increased 
with advancing stage, the percentage receiving surgery 
decreased with advancing stage. This likely reflects the 
increasing difficulty of performing more extensive 
surgical resections, even among those with stage IA–IIB 
disease.
uptake of MIs and rate of conversions
The use of MIS among surgically treated cases increased 
over time, up to 48.6% among stage IA cases in 2014. This 
increasing uptake of MIS was robust across the different 
conducted sensitivity analyses. Our findings are similar to 
those in a recent study, in which 44.5% of wedge resec-
tions and lobectomies among patients with non- metastatic 
lung cancer in Veterans Affairs hospitals between 2012 
and 2015 were conducted using VATS.14 The European 
Thoracic Surgery Database, which collects data from 170 
hospitals across 22 European countries, reported that 
the uptake of VATS lobectomies increased from 5.4% in 
2007–2011 to 29.3% in 2012–2015.20 Thus, it appears that 
the uptake of MIS in Europe is also increasing, although 
its uptake may lag compared with the USA.20 In the UK, 
the uptake of MIS is similar to the USA; increasing from 
53.4% in 2016 to 55.8% in 2017.21 Rates of conversions 
were similar in the UK (10.6% of lobectomy and bilobec-
tomy procedures in 2017), compared with our US- based 
study (11.5% of lobectomy and bilobectomy procedures 
in 2014).21 The increasing use of MIS may particularly 
benefit patients with a reduced lung function or cardi-
opulmonary reserve, in whom this approach has been 
shown to reduce rates of pulmonary morbidity compared 
with open surgery.22
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While we confirm that the uptake of MIS is increasing, 
we add that the rate of conversions to open surgery 
decreased during the same period. This may reflect 
increasing experience of thoracic surgeons.23 Whereas 
the uptake of MIS decreased with advancing stage, the 
rate of conversions increased with advancing stage. This 
finding may be partly explained by the decreasing use of 
sublobar resections and the increasing use of pneumo-
nectomy with advancing stage. Indeed, the uptake of MIS 
was lower for more extensive resections (eg, pneumonec-
tomy < (bi)lobectomy < sublobar resection). These obser-
vations may reflect the technical difficulty of performing 
more extensive resections by MIS.
In the USA, annual lung cancer screening has been 
recommended for high- risk individuals.7 It has been esti-
mated that the full- scale implementation of lung cancer 
screening in the USA will shift the percentage of stage I 
diagnoses in the general population (which includes indi-
viduals that are not eligible for screening) from 22.2% 
to 30.6%.6 This will increase demand for lung cancer 
surgery in the USA by up to 37.0%.6 If screening is to 
be effective, these cases should receive optimal treatment 
by MIS resection in a high- volume hospital.24 25 There-
fore, we expect that the uptake of MIS in the USA will 
continue to increase in coming years. In Europe, lung 
cancer screening has not yet been implemented. Never-
theless, several European countries have expressed the 
intention to start planning for the implementation of 
lung cancer screening.8 Therefore, we expect that the 
uptake of MIS lung resections will continue to increase 
in Europe as well.
uptake of sbrt
Among patients with stage IA–IB NSCLC, the uptake of 
SBRT increased substantially between 2010 and 2014. 
This finding was robust to the different sensitivity anal-
yses. The increasing uptake of SBRT may particularly 
benefit patients with lung cancer with comorbidities, 
which can increase the risks related to surgery. In the 
Netherlands, Palma and colleagues demonstrated that an 
increased use of SBRT among patients with stage I NSCLC 
led to fewer untreated elderly patients.26 In our US- based 
study, the overall percentage of early stage patients that 
received radiotherapy (both SBRT and conventional 
radiotherapy) also increased (by 3.4 percentage points). 
However, we did not find a corresponding reduction in 
the rate of non- treatment. Instead, we found that the 
percentage of early stage cases that received surgery 
decreased by 3.5 percentage points. This suggests a 
possible shift from operable patients towards medically 
inoperable patients (eg, due to comorbidities), which 
should be further investigated in future studies. The 
constant non- treatment rate of approximately 10% 
suggests possibilities for a further increase in the use of 
radiotherapy, and in particular SBRT, among early stage 
cases that would otherwise not receive any treatment.
Currently, SBRT is only recommended for medically 
inoperable early stage NSCLC cases. However, some 
studies have suggested that SBRT may be feasible in 
medically operable patients,27 which could increase the 
future uptake of SBRT. Because lung cancer screening 
is only recommended for patients fit to undergo cura-
tive lung surgery,7 it’s continued implementation may 
not directly increase the future use of SBRT. However, 
in practice it may be difficult to assess fitness for surgery 
prior to screening. Therefore, the increase in early stage 
cases due to screening may still lead to a further increase 
in the use of SBRT. Consequently, it is likely that the 
uptake of SBRT will continue to increase.
The uptake of SBRT was modest but present among 
stages IIA and IIB. This is most likely due to concerns 
about either lymph node involvement, tumour size or size 
of the irradiated field. SBRT is indeed most appropriate 
for tumours smaller than 5 cm (which encompasses stage 
I–IIA). Nevertheless, SBRT may also be used for larger 
isolated tumours (T1–3, N0, M0).5 28
strengths and limitations
The most important strength of this current analysis 
is the use of the NCDB data set, which captures treat-
ment data on 70% of incident cancer cases in the USA. 
Although this database is facility- based, an earlier report 
found no major differences in the distributions of sex, 
age, race or ethnicity, health insurance status, histology, 
and stage between lung cancer cases in the NCDB and 
the population- based Surveillance, Epidemiology, and 
End Results data set.17 Therefore, in contrast to previous 
reports, the findings of our study are likely representative 
for the general US population.14
A possible limitation of our study is the lack of clinical 
information in the NCDB, such as performance status. 
Therefore, we could not determine whether cases were 
medically operable or not. Future research is necessary 
to determine whether cases that do not receive any treat-
ment may have been medically eligible for surgery or 
SBRT.
A second possible limitation of using cancer registry 
data is that coding practices may change over time. 
However, the AJCC seventh edition staging manual was 
almost exclusively used during the study time period, 
which limits changes in study eligibility over time. In 
addition, no changes occurred in the coding of any of the 
outcome variables (eg, surgical approach, surgical extent 
or radiation modality).
A third limitation is that we did not assess whether 
the increasing use of MIS and SBRT affected patient 
outcomes. The NCDB does not include patient- reported 
outcomes, such as quality of life. In addition, we feel 
that a prospective randomised trial is the best method to 
provide an unbiased comparison of oncological outcomes 
across treatment modalities. Recently, the prospective 
VIdeo- assisted thoracoscopic lobectomy vs conventional 
Open LobEcTomy for lung cancer Trial confirmed that 
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that VATS lobectomy is associated with significantly 
lower in- hospital complications and a shorter length 
of stay than open lobectomy, without compromising 
oncological outcomes.29 Another recent prospective 
randomised controlled trial, which included inoperable 
stage I NSCLC cases, showed that SBRT provides superior 
tumour control compared with standard radiotherapy, 
without increasing toxicity.30 These studies indicate that 
the increasing uptake of MIS and SBRT in the USA will 
likely provide clinical benefit to patients with early stage 
NSCLC.
conclusIons
In conclusion, patterns of care show that surgeons in the 
USA have been increasingly using MIS to treat early stage 
NSCLC while the rate of conversions decreased. SBRT is 
also increasingly used. The increasing uptake of MIS and 
SBRT may particularly benefit patients with lung cancer at 
higher operative risk. Nevertheless, the increasing use of 
radiotherapy does not seem to coincide with a reduction 
in the percentage of cases that do not receive any treat-
ment. Therefore, there may be room for an additional 
increase in the use of radiotherapy, and in particular 
SBRT, among cases that would otherwise receive no treat-
ment. Continuing the increasing trends in uptake of MIS 
and SBRT may contribute to improving overall patient 
care, in particular with the expected increase in early 
stage lung cancer due to the implementation of lung 
cancer screening.
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